Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Allogene Therapeutics, Inc. (ALLO : NSDQ)
 
 • Company Description   
Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical stage. Allogene Therapeutics, Inc. is headquartered in South San Francisco, California.

Number of Employees: 310

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.48 Daily Weekly Monthly
20 Day Moving Average: 2,351,783 shares
Shares Outstanding: 143.60 (millions)
Market Capitalization: $1,074.13 (millions)
Beta: 0.88
52 Week High: $27.86
52 Week Low: $6.43
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.71% 10.69%
12 Week -19.13% -11.11%
Year To Date -49.87% -38.17%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
210 EAST GRAND AVENUE
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-457-2700
fax: -
ir@allogene.com http://www.allogene.com
 
 • General Corporate Information   
Officers
David Chang - President; Chief Executive Officer
Arie Belldegrun - Executive Chairman
Eric Schmidt - Chief Financial Officer
Elizabeth Barrett - Director
David Bonderman - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 019770106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 143.60
Most Recent Split Date: (:1)
Beta: 0.88
Market Capitalization: $1,074.13 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.59 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.26
Price/Cash Flow: -
Price / Sales: 5,239.65
EPS Growth
vs. Year Ago Period: -124.00%
vs. Previous Quarter: -3.70%
Sales Growth
vs. Year Ago Period: -99.84%
vs. Previous Quarter: 19.61%
ROE
03/31/22 - -32.28
12/31/21 - -25.83
09/30/21 - -24.20
ROA
03/31/22 - -28.87
12/31/21 - -23.24
09/30/21 - -21.74
Current Ratio
03/31/22 - 12.74
12/31/21 - 9.78
09/30/21 - 9.40
Quick Ratio
03/31/22 - 12.74
12/31/21 - 9.78
09/30/21 - 9.40
Operating Margin
03/31/22 - -148,214.64
12/31/21 - -667.74
09/30/21 - -
Net Margin
03/31/22 - -148,214.64
12/31/21 - -667.74
09/30/21 - -
Pre-Tax Margin
03/31/22 - -148,214.66
12/31/21 - -667.74
09/30/21 - -652.24
Book Value
03/31/22 - 5.96
12/31/21 - 6.43
09/30/21 - 6.82
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©